stockportfolio.pro
Geron Corporation (GERN)
Healthcare · Biotechnology · NasdaqGS
Geron Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.16M | $1.06M | $1.07M | $460,000 | $253,000 | $1.39M | $596,000 | $237,000 | $76.99M | $183.88M |
| Gross profit | — | — | — | — | — | — | $596,000 | $237,000 | $75.74M | $179.14M |
| Net income | $-29.54M | $-27.92M | $-27.02M | $-68.55M | $-75.62M | $-116.11M | $-141.90M | $-184.13M | $-174.57M | $-83.50M |
| Net margin | -479.3% | -2621.2% | -2534.4% | -14901.7% | -29888.1% | -8335.4% | -23808.9% | -77690.7% | -226.7% | -45.4% |
Source: Geron Corporation SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Geron Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GERN in your portfolio →
Geron Corporation financial history by metric
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation — frequently asked questions
What is Geron Corporation's revenue?
Geron Corporation (GERN) reported revenue of $183.88M for fiscal year 2025, up 138.8% from the prior year, according to its SEC filings.
Is Geron Corporation profitable?
No — GERN reported a net loss of $-83.50M in fiscal 2025.
What is GERN's P/E ratio?
Geron Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Geron Corporation growing?
GERN's revenue grew at roughly 273.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Geron Corporation have?
As of fiscal year 2025, GERN carried roughly $119.55M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Geron Corporation's gross margin?
GERN's gross margin was 97.4% in fiscal 2025 — gross profit of $179.14M on revenue of $183.88M.
What is Geron Corporation's market cap?
Geron Corporation (GERN) has a market capitalization of about $734.54M, based on the latest data in our nightly-refreshed cache.
When does Geron Corporation's fiscal year end?
GERN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Geron Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.